A2M in Colorectal Cancer (ISSN 2753-8176 (online))

1.Ana Pedro

1.Gwyntwr1386 Health & Social Care, Harold Tomlin Day Centre, 24 Grosvenor Street, Chester, CH1 2DD. info@gwyntwr1386.com

Colorectal cancer (CRC), is the development of cancer from the colon or rectum (parts of the large intestine). Staging of the cancer is based on both radiological and pathological findings. As with most other forms of cancer, tumor staging is based on the TNM system which considers how much the initial tumor has spread and the presence of metastases in lymph nodes and more distant organs. We analyze the possibility that A2M (alpha-2-macroglobulin) can play a role in CRC initiation and/or progression. Here, we analyze by proteomics the presence of A2M in the conditioned culture media of different CRC cell lines either overexpressing P53 or knockout for P53 (3) or treated with vitamin D and from different stages of tumor progression and benign tissues (table 1).

We found out that A2M mascot score in primary tumor cells lines compared with control is either similar or very reduced, being slightly reduced in cell lines treated with vitamin D and /or overexpressing P53. Finally, A2M mascot score is moderately reduced in the metastatic cell line, SW620.

Vitamin D3 has been estimated to lower the incidence of colorectal cancer by 50%, which is consistent with the inverse correlation between dietary vitamin D3 intake or sunlight exposure and human colorectal cancer. Both A2M and Vitamin D play a role in the immune and inflammatory response. A2M acts as a protease inhibitor and cytokine binder, while vitamin D modulates the activity of immune cells. This suggests that A2M may have a role in inhibiting CRC initiation and progression.

Methods

Proteomic analysis was performed at the Rockefeller University, Proteomics Center as described in Hamidi et al., 2017. Only proteins with Mascot scores of approximately 90 or >90 were considered. The proteomic analysis excel files and each correspondent sample details were generously and kindly shared and donated by Dr. David Lyden, Weill Cornell Medical College, New York, USA. Original data files can be found at https://zenodo.org/record/7422331#.Y5THeXbP3IU

References:

1. "Colon Cancer Treatment (PDQ®)". NCI. May 12, 2014.

2.Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N (March 2010). "Colorectal cancer". Lancet. 375 (9719): 1030–1047.

3. Taieb and Gallois (2020). Adjuvant Chemotherapy for Stage III Colon Cancer. Cancers (Basel), 12(9): 2679.

4. Gvirtzman, et al (2021). Anemia can predict the prognosis of colorectal cancer in the pre-operative stage: a retrospective analysis. World Journal of Surgical Oncology 19, Article number: 341

5. Zheng et al (2017). Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination. Nature Communications 8, Article number: 14344

6. Boughanem et al. Vitamin D Intake and the Risk of Colorectal Cancer: An Updated Meta-Analysis and Systematic Review of Case-Control and Prospective Cohort Studies. Cancers (Basel). 2021 Jun; 13(11): 2814.

7.https://www.atcc.org/products/ccl-227#:~:text=SW620%20%5BSW%2D620%5D%20cells,for%20cancer%20and%20toxicology%20research.&text=Discounts%20may%20be%20available%20for%20our%20fellow%20nonprofit%20organizations.

8.https://www.atcc.org/products/ccl-247

9.https://www.atcc.org/products/htb-38#:~:text=HT%2D29%20is%20a%20cell,in%20cancer%20and%20toxicology%20research.

10. Klampfer, L (2014).Vitamin D and colon cancer. World J Gastrointest Oncol. 6(11): 430-437